

Apple Health PDL Drug Class Motions

February 16, 2022

Antibiotics & Respiratory Agents

- ▶ Aminoglycosides – Inhaled
- ▶ Monobactams – Inhaled
- ▶ Cystic Fibrosis Agents
- ▶ Cystic Fibrosis Agents- CFTR Potentiators

Antibiotics & Respiratory Agents

▶ Recommendation:

- ▶ All products listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Antibiotics & Respiratory Agents

Motion: I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Marcotte**
- ▶ **2nd: Schwilke**

Anticoagulants : Factor XA And Thrombin Inhibitors - Oral

▶ Recommendation:

- ▶ All products in the Anticoagulants : Factor XA And Thrombin Inhibitors – Oral drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Anticoagulants : Factor XA And Thrombin Inhibitors - Oral

▶ **Motion:** I move that all products in the Anticoagulants : Factor XA And Thrombin Inhibitors – Oral drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion: Chawla**

▶ **2nd: Beste**

Antidiabetics

- ▶ Amylin Analogs
- ▶ DPP4 Inhibitor / SGLT2 Inhibitor Combinations
- ▶ DPP4 Inhibitor / TZD Combinations
- ▶ DPP4 Inhibitors
- ▶ GLP1 Agonist / Insulin Combinations
- ▶ GLP1 Agonists
- ▶ Insulin - Intermediate Acting
- ▶ Insulin - Long Acting

Antidiabetics

- ▶ Insulin - Pre-Mixed
- ▶ Insulin - Rapid Acting
- ▶ Insulin - Short Acting
- ▶ SGLT2 Inhibitors

Antidiabetics

▶ Recommendation:

- ▶ All products listed on slides 7 and 8 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Antidiabetics

Motion: I move that all products in the drug classes listed on slides 7 and 8 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. There must be at least one preferred product in each Antidiabetic subclass, with proven cardiovascular and nephroprotective benefit if applicable. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Chawla**
- ▶ **2nd: Marcotte**